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Background: The study was conducted to assess outcomes among women using the levonorgestrel-releasing intrauterine system (LNG-IUS).
Study Design: The data were collected via a retrospective claims database analysis of 152 women. Two nested cohorts were further
distinguished based on length of follow-up: two and three continuous years (n=73 and n=29, respectively).
Results: Over 90% had a single insertion, and fewer than 4% experienced an LNG-IUS-related complication. Thirteen percent of women
experienced menorrhagia in the year preceding insertion; this figure dropped to 12.5%, 1.2% and 0% in the 1, 2 and 3 years postinsertion.
Mean number of gynecology-related visits decreased from four to two in the overall cohort, from seven to four in the cohort with 2 years of
follow-up and from nine to four in the cohort with 3 years of follow-up.
Conclusion: LNG-IUS use prevented pregnancy in all patients and was associated with decreased vaginal bleeding starting in the second
year postinsertion.
© 2008 Elsevier Inc. Open access under CC BY-NC-ND license.Keywords: LNG-IUS; Retrospective; Outcomes1. Introduction
In 2001, there were 1.4 million physician visits in the
United States for excessive uterine bleeding [1]. Every year,
more than 5% of women aged 30–49 years present to their
general practitioner with menorrhagia, and more than 12% of
referrals to gynecologists are related to menorrhagia [2].
Menorrhagia is typically defined as prolonged and/or heavy
menstrual bleeding (i.e., total menstrual blood loss of more
than 80 mL per cycle) occurring cyclically and over several
consecutive cycles [3]. Other terms used to describe
disturbances of menstruation include abnormal uterine
bleeding (AUB) and dysfunctional uterine bleeding
(DUB). These terms have been heavily debated over time☆ Funding was provided by Bayer Healthcare Pharmaceuticals, Inc.
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8601.
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Open access under CC BY-NC-ND license.[4]; however, regardless of the classification of the type of
bleeding, women with heavy menstrual bleeding have a 43%
prevalence of anemia [5] and a 60% probability of under-
going a hysterectomy within 5 years [6].
Traditional medical management for irregular, heavy
bleeding has consisted of tranexamic acid, nonsteroidal anti-
inflammatory drugs (NSAIDs), oral progestins or oral
contraceptives. However, these treatments are often ineffec-
tive, requiring many women to undergo subsequent surgical
procedures such as endometrial resection, endometrial
ablation or hysterectomy [7]. The levonorgestrel-releasing
intrauterine system (LNG-IUS), a contraceptive marketed as
Mirena®, provides a viable alternative to invasive surgery in
women with irregular, heavy bleeding. While relatively new
to the US market (the LNG-IUS was approved by the FDA in
late 2000) and unpopular among US women, the device was
studied extensively in Europe [8–13] for more than a decade
prior to receiving US approval and has proven to be effective
in the treatment of heavy menstrual bleeding [14].
Table 1
Codes for LNG-IUS insertion and removal
Codes for insertion of LNG-IUS
Henry Ford 70321531 Charge code for LNG-IUS
HCPCS J7302 LNG-IUS
HCPCS S4981 Insertion of LNG-IUS
Codes for removal of LNG-IUS: any of the above, OR:
CPT 58301 Removal of intrauterine device (unspecified)
HCPCS J7300 Copper T-380A intrauterine device




Insertion of intrauterine contraceptive
device (unspecified)
ICD-9 Procedure Code 69.7 Insertion of intrauterine contraceptive
device (unspecified)
CPT 58300 Insertion of intrauterine device (unspecified)
ICD-9 Diagnosis Code
996.32




Infection and inflammatory reaction
due to intrauterine contraceptive device
ICD-9 Diagnosis Code
996.76
Hemorrhage due to presence of
genitourinary device, implant or graft
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reversible) morphologic effects on the endometrium [15] as
endometrial growth is suppressed by continuous exposure to
levonorgestrel [16]. Over time, this has been shown to
produce reduced menstrual flow, with up to 50% of users
becoming amenorrheic after 12 months (substantially higher
than the 20% reported in package labeling) [17,18]. The
effect on menstrual flow has led researchers to examine the
LNG-IUS as a treatment for menorrhagia, an indication
already approved for this device in several countries
[7,19,20]. The LNG-IUS has proven considerably more
effective than NSAIDs in menorrhagia management [20]. In
addition, the LNG-IUS has been found to be as effective as
oral norethisterone in treating menorrhagia. In one study, the
LNG-IUS reduced menstrual blood loss by an average of
94% after 3 months, comparable to the 87% reduction in
long-cycle oral norethisterone users [19]. Method satisfac-
tion differed dramatically; however, following three cyclesFig. 1. Study cohorts and fof treatment, 76% of the LNG-IUS group wished to continue
treatment compared with 22% of the norethisterone users.
The objectives of this retrospective pre-post cohort study
were to describe a real-world population of women who have
received LNG-IUS and assess the contraceptive and
noncontraceptive benefits over time.2. Materials and methods
2.1. Database description and study design
This study utilized a retrospective pre-post cohort design,
with data extracted from the Henry Ford Health System
(HFHS) linked claims database. HFHS is a large, vertically
integrated health care system serving the primary and specialty
health care needs of residents in theMidwestern United States;
care is provided to over 2.5 million patient contacts annually.
Approximately 60% of HFHS members are part of a large,
nonprofit, mixed-model HMO (Health Alliance Plan, or HAP)
that includes a substantial number of Medicare and Medicaid
patients. For HAP enrollees, the database contains information
for all health-related encounters that occurred within or
outside of HFHS for the duration of HAP enrollment.
2.2. Patient population
The patient population was selected from the HFHS
database using the following inclusion criteria: (1) patients
18 years of age and older, (2) at least one insertion of an
LNG-IUS between 2000 and 2005 [based on Henry Ford and
Health Care Procedure Coding System (HCPCS) [21] codes,
see Table 1] and (3) at least 1 year of continuous HAP
enrollment both pre- and post-LNG-IUS insertion. Index
date was defined as the first date of insertion of an LNG-IUS
appearing in the database. Fig. 1 presents the study cohort in
schematic form.
Analyses were performed on the overall patient population
as well as on two nested subpopulations: those with 2 years of
continuous HAP enrollment both pre- and postindex date and
those with 3 years. Patients were included in all analyses forollow-up schematic.
able 2












ean age at index date
in years (SD)
34.6 (7.5) 35.0 (7.7) 36.0 (6.5)
ace, n (%)
Black 68 (45) 33 (45) 12 (41)
White 64 (42) 35 (48) 15 (52)
Other 20 (13) 5 (7) 2 (7)
ean Charlson
Comorbidity Index (SD)
0.4 (0.7) 0.5 (0.8) 0.4 (0.6)
arous, n (%) 107 (70) 55 (75) 21 (72)
ravidous, n (%) 117 (77) 57 (78) 22 (76)
ontraceptive use
preindex, n (%)
69 (45) 46 (63) 20 (69)
Index year, n (%)
2002 36 (24) 30 (41) 22 (76)
2003 51 (34) 32 (44) 7 (24)
2004 57 (37) 11 (15) 0
2005 8 (5) 0 0
uration of HAP
enrollment in years (SD)
Preindex 6.5 (4.9) 7.3 (4.6) 7.4 (3.8)
Postindex 2.3 (0.9) 3.0 (0.6) 3.4 (0.3)
atterns of LNG-IUS use
umber of LNG-IUS
insertions, n (%)
One 139 (91) 68 (94) 28 (97)
Two 12 (8) 4 (5) 1 (3)
Three 1 (1) 1 (1) 0 (0)
umber of patients with
LNG-IUS removal during
postindex period, n (%)
41 (27%) 24 (33%) 7 (24%)
ean time to removal 5 (4) 9 (7) 13 (10)
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3-year analysis were also included in the 1- and 2-year
analyses (Fig. 1).
2.3. Statistical analyses
The study database was checked for accuracy, consis-
tency and completeness; data cleaning was performed as
necessary. Descriptive statistics were performed at baseline
to summarize the demographic characteristics of each of the
study populations. Frequencies (for categorical variables)
and distributions (for continuous variables) were examined
for the following variables: age at index date, race, Charlson
Comorbidity Index,1 parity (having previously given birth to
an offspring), gravidity (having previously been pregnant)
and use of hormonal contraception (oral, transdermal,
injectable or vaginal, based on National Drug Codes) in
the year preceding insertion of the LNG-IUS.
Year of LNG-IUS insertion (i.e., index year) and duration
of HAP enrollment pre- and postinsertion were reported.
Removal of the LNG-IUS was determined by an algorithm
that searched the database for any the following events: (1) A
Current Procedural Terminology (CPT) Plus [22] code for
removal of an intrauterine device, (2) a second IUD insertion
code or (3) an ICD-9 diagnosis code [23] for an LNG-IUS-
related complication (see Table 1 for codes). The first date of
any of the above events was considered the date of removal;
if none of the above were present, the LNG-IUSwas assumed
to have remained intact for the duration of the postinsertion
follow-up. Distribution of mean length of time on the LNG-
IUS was calculated for patients with an identified removal;
frequencies of additional insertions and related complications
were calculated for the patient populations.
Contraceptive and noncontraceptive outcomes were
examined and compared in the pre- and postinsertion
periods. Frequencies of menorrhagia, AUB, DUB, dysme-
norrhea and anemia were determined in the pre- and
postindex periods using ICD-9 codes. A time-trend analysis
was conducted to determine rates of relevant bleeding
disorders in the year preindex and in 1-year increments over
3 years postinsertion; each increment included all patients
with full HAP follow-up.
Frequency of hysterectomy was calculated in the patient
population. Numbers of obstetric- and gynecology-related
encounters within the health care system (based on ICD-9
and CPTcodes) were calculated for the pre- and postinsertion
periods among nonhysterectomized women only. The
rationale for excluding hysterectomized women was that
hysterectomy, by definition, could occur only in the
postindex period. A comparison of obstetric-related encoun-
ters from the preindex to the postindex period would1 The Charlson Comorbidity Index is a summary measure of disease
burden based on International Classification of Diseases, Ninth Edition
(ICD-9) [22] diagnosis codes for chronic conditions in the year prior to
index date and scaled from 0 to 34 with 34 representing the highest
comorbidity burden [23].therefore be biased because women cannot become pregnant
posthysterectomy; a comparison of gynecology-related
encounters would be biased as well because hysterectomy
was associated with a postindex surge in resource utilization
that could not be borne in the preindex period. All statistical
analyses were conducted using SAS version 9.1 (SAS
Institute Inc., Cary, NC).3. Results
3.1. Population description
Results from the descriptive analysis are summarized in
Table 2. Overall, the population of patients with 1 year of
HAP enrollment pre- and postinsertion consisted of 152
women (mean age, 35 ± 8). The 2-year population consisted
of 73 women (mean age, 35 ± 8), while the 3-year population
size was 29 (mean age, 36 ± 7). The overall patientin months a (SD)
umber of patients with
LNG-IUS-related
complications, n (%)
4 (2.6%) 3 (4.1%) 1 (3.5%)
a Among the subset of patients who had an LNG-IUS removal within

















ig. 2. Proportion of patients experiencing bleeding events — time-trend
nalysis. Bleeding outcomes include menorrhagia, dysmenorrhea, DUB and
UB. Only one event is counted per patient per follow-up period. Each
hole bar represents the total percentage of patients experiencing any
leeding outcome.
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was 0.4 ± 0.7), and over 40% of women self-reported being
African American. Over 76% of women were identified as
gravidous, and 70% were parous at baseline.
3.2. Patterns of LNG-IUS use
The patterns of LNG-IUS use are also summarized in
Table 2. Over 90% of women in all study populations had a
single LNG-IUS insertion, while 3–8% of women had two
insertions and 1% or fewer had three insertions over the
duration of follow-up. Among women who had the LNG-
IUS removed before the end of follow-up (24–33% of
patients), mean time to removal ranged from 5 months for the
1-year population to 13 months for the 3-year populations.
Four patients (2.6%), 3 patients (4.1%) and 1 patient (3.5%)
experienced an LNG-IUS-related complication (e.g., expul-
sion, perforation or infection) in the 1-, 2- and 3-year
populations, respectively.
3.3. Contraceptive benefits of the LNG-IUS
No patient experienced a pregnancy while the LNG-IUS
was inserted. Themean number of obstetric-related encounters
in the health system among nonhysterectomized women in
the pre- and postinsertion periods is presented in Table 3. The
mean numbers of preinsertion visits were 6 ± 8 in the 1-year
population, 9 ± 13 in the 2-year population and 9 ± 12 in
the 3-year population. The mean number of postinsertion
obstetric visits was zero (or close to zero) for all populations.
3.4. Noncontraceptive benefits of the LNG-IUS
Fig. 2 shows the percentage of patients experiencing any
one, two or three bleeding outcomes using a time-trend
analysis. Each patient with bleeding was counted only once
per year of follow-up; fewer than 25% of the study population
experienced a bleeding disorder at any point during the study.
Among those patients who did have bleeding, most (∼73%)
experienced only a single bleeding outcome, and no patient
experienced all four bleeding events (the maximum number
of separate bleeding conditions experienced by any one
patient was three). The percentage of patients experiencing
bleeding disorders was not markedly different in the year
immediately following insertion compared to the year
preinsertion; however, there was a notable decline in bleeding
outcomes in the second year following insertion, with no
patient experiencing irregular, heavy bleeding in the thirdTable 3












Preindex 6.2 (8.3) 9.2 (12.6) 9.4 (12.3)
Postindex 0 (0) 0.3 (1.9) 0 (0)
Mean gynecology-
related visits (SD)
Preindex 4.0 (3.2) 6.9 (4.9) 8.7 (5.8)




byear. Fig. 3 shows a time-trend analysis of each individual
bleeding condition. Fewer than 14% of patients experi-
enced menorrhagia or AUB, fewer than 6% had DUB or
dysmenorrhea and fewer than 3% became anemic. The
prevalence of each bleeding outcome was similar in the
1-year preinsertion and 1-year postinsertion periods, and
the prevalence of all bleeding outcomes except DUB
decreased in the second year postinsertion to frequencies
lower than in the preinsertion period (menorrhagia and
AUB by approximately 88%; dysmenorrhea and anemia by
100%). By the third year postinsertion, none of the women
in the study population experienced a bleeding outcome.
Mean numbers of gynecology-related visits pre- and post-
LNG-IUS are presented in Table 3. The number of
gynecology-related visits decreased in the postindex period
for all follow-up periods (from four visits to two in the 1-year
population, from seven visits to four in the 2-year populationFig. 3. A time-trend analysis of specific bleeding conditions.
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planning advice was the most common reason for a
gynecologist visit both pre- and postindex; other reasons
included menorrhagia in the preindex period and IUD-
related inquiries (i.e., checking, insertion and removal) in the
postindex period.4. Discussion
Data from this study demonstrate both the contraceptive
and noncontraceptive clinical benefits of the LNG-IUS in a
real-world population of women. The contraceptive benefits
of the LNG-IUS have already been firmly established; once
inserted, it is over 99% effective at preventing pregnancy
[24]. Noncontraceptive benefits demonstrated in this study
include a reduction in vaginal bleeding symptoms that
became more apparent over time, as well as a concurrent
reduction in health care system utilization. Results of the
bleeding analysis are consistent with clinical trial literature
establishing the LNG-IUS as an effective treatment for a
variety of bleeding disorders. In a systematic review
published in 2001, the LNG-IUS was found to reduce
menstrual blood loss by 74% to 97% in women with
irregular, heavy bleeding, a significantly greater effect than
that of medical regimens such as tranexamic acid (44%,
pb.01) and flurbiprofen (21%, pb.001) [25]. Given these
findings, US physicians should provide ample counseling to
patients on the benefits of LNG-IUS, which may raise
acceptance to levels seen in their European counterparts.
Four women (2.6%) underwent a hysterectomy during
study follow-up. While no claims can be made as to whether
more hysterectomies were avoided due to LNG-IUS use,
avoidance of surgery has been a demonstrated benefit of the
LNG-IUS in the published reports. Studies have reported that
64% to 82% of women slated for bleeding-related hyster-
ectomies opted to forego the procedure after using the LNG-
IUS for treatment, compared with fewer than 20% of those
using traditional medical management [7,26–28]. Addition-
ally, Bongers et al. [3] have shown that 77% of women with
irregular, heavy bleeding whose medical therapies fail go on
to have a surgical procedure. In 30% of these cases, a
hysterectomy is necessary to treat persistent bleeding. Thus,
approximately a quarter (23%) of the women who present
with irregular, heavy bleeding and are unsuccessful with
medication therapy eventually have a hysterectomy. While
our sample size was insufficient to show a statistically
significant reduction in bleeding, no patient in the study
population experienced a bleeding disorder by the third year
postinsertion, compared with 25% of patients in the year
prior to insertion. Additionally, in a randomized trial, the
LNG-IUS scored as well in the treatment of bleeding as
hysterectomy at 12 months in terms of health status, health-
related quality of life and psychological well-being [27].
Given the high percentage of women with these bleeding
conditions who have required hysterectomy in the past, theLNG-IUS has the potential to substantially reduce the
frequency of this major, invasive surgery.
Trussell et al [29] found intrauterine contraception to be
the most cost-effective form of birth control if left intact for
over 3 years. An analysis establishing the cost-effectiveness
of the LNG-IUS in the treatment of bleeding was out of the
scope of this study; however, our results suggest greater cost-
effectiveness with a longer duration of use. The economic
benefits derived from preventing invasive and costly
procedures such as ablation or hysterectomy to treat
irregular, heavy bleeding are potentially high and should
be investigated further.
Our study has several limitations. The LNG-IUS was
FDA-approved as a contraceptive device in 2000, limiting
the amount of follow-up obtainable within the study
population. Additionally, intrauterine contraception is used
by approximately 1% of women of childbearing age in the
United States, further limiting our sample size. Our
database search did not yield enough study subjects to
make meaningful statistical comparisons from the pre-to the
postindex period; small sample size was a particular
problem in studying subpopulations with longer follow-
up, where long-term benefits of the LNG-IUS may be more
apparent. Additionally, claims data provide an imperfect
proxy for true resource utilization and may not reflect all
clinical nuances experienced by the population. Indeed,
there was a degree of overlap in terms of classifying the
following bleeding episodes: menorrhagia (excessive reg-
ular menstrual bleeding, included in the same ICD-9 code
as frequent menstrual bleeding), dysmenorrhea (pain during
regular menstruation), DUB (excessive menstrual bleeding
in the absence of structural abnormality, included in the
same ICD-9 code as functional uterine hemorrhage), AUB
(absent, infrequent, postcoital, intermenstrual or irregular
bleeding) and anemia (including iron deficiency, non-
autoimmune hemolytic anemia and acute posthemorrhagic
anemia) [23].
The HFHS population is drawn from a single large, urban
area in the United States whose population may not perfectly
mirror that of the United States overall, particularly in terms
of racial composition and personal physician practice
patterns (we do not know the demographics or numbers of
physicians responsible for the 152 insertions, for example).
Furthermore, HAP members represent a unique subsection
of the Henry Ford population. Although it is difficult to
generalize our study findings for the overall U.S. population,
or for overall physician prescribing patterns, LNG-IUS-
related complication rates found in our study are comparable
to that of the general population for expulsion (2–10%
spontaneous expulsions within the first year) [24], perfora-
tions (1 per 1000 correct insertions lead to a perforation) [30]
and pelvic inflammatory disease (1.6 cases per 1000 woman-
years of IUD use) [31]. It should be noted that the rate of
pelvic inflammatory disease reported in this article is for the
copper IUD and therefore may be higher than noncopper
IUD rates.
41S.K. Hendlish et al. / Contraception 78 (2008) 36–41To the best of our knowledge, this study represents the
first analysis of patterns of LNG-IUS use and subsequent
contraceptive and noncontraceptive outcomes in a real-world
managed care population. Further study of the economic
benefits of the LNG-IUS is needed, particularly with respect
to the potential impact on budgets for the treatment of
bleeding disorders. As the LNG-IUS remains on the market
for a longer period of time in the United States, it will
become possible to study its impact in larger patient
populations with longer follow-up.
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